JAMPRO
The Jamaica Promotions Corporation (JAMPRO) will be staging Explore: Do Business Jamaica Virtual Investment Conference (DBJVIC) from November 17 – 18, 2021 to introduce local and international investors to business opportunities in the island’s growing industries.
The event will showcase emerging projects and new developments in Agribusiness, Outsourcing, Manufacturing, Energy, Tourism, and the Creative Industries through over 30 panels, interviews and discussions with government and business leaders. The investment conference aims to foster business and stakeholder relationships and will shed light on Jamaica’s COVID-19 economic recovery efforts.
The conference will be staged concurrently via two platforms; one is a virtual interactive business event portal that will facilitate a real-time engagement experience and B2B meetings, the second is a live stream event via social media that will accommodate and drive increased awareness of Jamaica’s economic progress. This format will help JAMPRO to engage attendees including current and potential investors, JAMPRO clients, private and public sector stakeholders, and diplomatic missions.
JAMPRO anticipates extensive global participation based on the planned international promotions which will ensure the leveraging of the virtual B2B meeting platform by potential investors.
New opportunity to do business
Speaking on the event, Jamaica’s Minister of Industry, Investment, and Commerce, The Honourable Audley Shaw, CD, MP., noted that the virtual investment conference has presented a new opportunity for the government to amplify the promotion of Jamaica’s business opportunities.
He explained, “This virtual conference will allow us to reach and directly engage investors across the globe who are interested in doing business with Jamaica but need further market intelligence and guidance on the potential that is available in the island’s sectors. From our perspective, it is the right time to host this global event, as persons are seeking new ventures as the world slowly returns to normality .”
Diane Edwards, President of JAMPRO, echoed the Minister’s statements, and expressed confidence in the conference’s ability to deliver results for Jamaica and attendees, she said, “The format of the conference is powerful, because it presents an excellent opportunity for global business leaders to get valuable insight on Jamaican investment opportunities, engage their colleagues in various industries, and explore bankable projects, all in the location of their choice. We believe that this conference will lead to the development of lucrative partnerships and financial opportunities for local and international investors. ”
Persons can register for the event at explore.dobusinessjamaica.com
ABOUT THE EXPLORE: DO BUSINESS JAMAICA VIRTUAL INVESTMENT CONFERENCE (DBJVIC)
Explore: Do Business Jamaica Virtual Investment Conference is a 2-day event that will highlight investment and other business opportunities in Jamaica. The event, hosted by Jamaica’s investment and export promotion agency, JAMPRO, will provide a platform for attendees to learn more about Jamaican investment opportunities, see lucrative projects, and build business relationships.
Explore Do Business Jamaica Virtual Investment Conference is sponsored by the Foundations for Competitiveness and Growth Project (FCGP), National Commercial Bank (NCB), Mystique Integrated, and M-One Productions
For more information on the conference, please visit https://explore.dobusinessjamaica.com/ .
Follow JAMPRO on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005861/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom